Search results
New gene delivery vehicle shows promise for human brain gene therapy
Medical Xpress· 3 hours agoGene therapy could potentially treat a range of severe genetic brain disorders, which currently have no cures and few treatment options. The enormous challenge of getting therapies past this ...
Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials...
FOX 23 News Albany· 1 day agoRactigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering...
AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's...
Digital Journal· 4 days agoSTOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...
'Trojan Horse' weight loss drug found to be more effective than available therapies
Medical Xpress· 6 hours agoIn a study published in Nature, Christoffer Clemmensen and colleagues demonstrate a new use of the weight loss hormone GLP-1. GLP-1 can be used as a "Trojan Horse" to smuggle a specific molecule ...
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 16 hours agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...
New $500 million NCInnovation program awards first grants. Here’s where money is going
The News & Observer· 2 hours agoLithium refining, honeybee hive production and a solution to power-grid failures are among the initial batch of university projects a new taxpayer-backed state organization is betting on to ...
'Trojan horse' weight loss drug more effective than available therapies
Science Daily· 2 days agoIn the study, Christoffer Clemmensen and colleagues demonstrate a new use of the weight loss hormone GLP-1. GLP-1 can be used as a 'Trojan Horse' to smuggle a specific molecule into the brain ...
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Digital Journal· 2 days agoTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
Zacks· 16 hours agoFree Report) announced positive results from an early-stage study evaluating one of its recently...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 7 hours agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...